{"name":"Grifols","slug":"grifols","ticker":"GRF.MC","exchange":"BME","domain":"grifols.com","description":"Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.","hq":"Barcelona, Spain","founded":1940,"employees":"25000","ceo":"Nacho Abia","sector":"Plasma-Derived Therapies / Biologics","stockPrice":9.18,"stockChange":0.38,"stockChangePercent":4.32,"marketCap":"$7.3B","metrics":{"revenue":8689252492.93271,"revenueGrowth":-4.8,"grossMargin":38.4,"rdSpend":0,"netIncome":484813084.50000006,"cash":820093458.6,"dividendYield":1.7,"peRatio":15.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"RhoGAM patent cliff ($1.1B at risk)","drug":"RhoGAM","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"HyperRAB S/D patent cliff ($500M at risk)","drug":"HyperRAB S/D","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Alphanate","genericName":"Alphanate","slug":"alphanate","indication":"Other","status":"discontinued"},{"name":"Diphtheria-Tetanus Toxoids Adsorbed","genericName":"Diphtheria-Tetanus Toxoids Adsorbed","slug":"diphtheria-tetanus-toxoids-adsorbed","indication":"Other","status":"marketed"},{"name":"Xembify","genericName":"Xembify","slug":"xembify","indication":"Other","status":"marketed"},{"name":"Albutein 20%","genericName":"Albutein 20%","slug":"albutein-20","indication":"Other","status":"phase_3"},{"name":"Alpha-1 MP","genericName":"Alpha-1 MP","slug":"alpha-1-mp","indication":"Other","status":"phase_3"},{"name":"GAMUNEX-C","genericName":"GAMUNEX-C","slug":"gamunex-c","indication":"Other","status":"marketed"},{"name":"IGSC 20%","genericName":"IGSC 20%","slug":"igsc-20","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"IGIV3I Grifols 10%","genericName":"IGIV3I Grifols 10%","slug":"igiv3i-grifols-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IGIV-C 10%","genericName":"IGIV-C 10%","slug":"igiv-c-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IVIG-PEG","genericName":"IVIG-PEG","slug":"ivig-peg","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"Immune Globulin (Human)","genericName":"Immune Globulin (Human)","slug":"immune-globulin-human","indication":"Primary immunodeficiency disorders","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Fibrin Sealant (FS) Grifols","genericName":"Fibrin Sealant (FS) Grifols","slug":"fibrin-sealant-fs-grifols","indication":"Hemostasis and tissue adhesion during surgical procedures","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Alphanate SD/HT","genericName":"Alphanate SD/HT","slug":"alphanate-sd-ht","indication":"Hemophilia A (congenital Factor VIII deficiency) — treatment and prevention of bleeding episodes","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Prolastin-C","genericName":"Prolastin-C","slug":"prolastin-c","indication":"Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)","status":"marketed"}]}],"pipeline":[{"name":"Alphanate","genericName":"Alphanate","slug":"alphanate","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Diphtheria-Tetanus Toxoids Adsorbed","genericName":"Diphtheria-Tetanus Toxoids Adsorbed","slug":"diphtheria-tetanus-toxoids-adsorbed","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Fibrin Sealant (FS) Grifols","genericName":"Fibrin Sealant (FS) Grifols","slug":"fibrin-sealant-fs-grifols","phase":"phase_3","mechanism":"Fibrin sealant is a topical hemostatic agent that forms a fibrin clot by combining fibrinogen and thrombin to achieve rapid hemostasis at surgical sites.","indications":["Hemostasis and tissue adhesion during surgical procedures","Control of bleeding in general surgery, cardiovascular surgery, and other surgical applications"],"catalyst":""},{"name":"IGIV3I Grifols 10%","genericName":"IGIV3I Grifols 10%","slug":"igiv3i-grifols-10","phase":"phase_3","mechanism":"IGIV3I is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune responses and provide immunoprotection.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"Xembify","genericName":"Xembify","slug":"xembify","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Albutein 20%","genericName":"Albutein 20%","slug":"albutein-20","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alpha-1 MP","genericName":"Alpha-1 MP","slug":"alpha-1-mp","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alphanate SD/HT","genericName":"Alphanate SD/HT","slug":"alphanate-sd-ht","phase":"marketed","mechanism":"Alphanate SD/HT is a plasma-derived Factor VIII concentrate that replaces deficient clotting factor VIII to restore hemostasis in patients with hemophilia A.","indications":["Hemophilia A (congenital Factor VIII deficiency) — treatment and prevention of bleeding episodes","Perioperative management in hemophilia A patients"],"catalyst":""},{"name":"GAMUNEX-C","genericName":"GAMUNEX-C","slug":"gamunex-c","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IGIV-C 10%","genericName":"IGIV-C 10%","slug":"igiv-c-10","phase":"phase_3","mechanism":"IGIV-C 10% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions","Autoimmune and inflammatory disorders"],"catalyst":""},{"name":"IGSC 20%","genericName":"IGSC 20%","slug":"igsc-20","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IVIG-PEG","genericName":"IVIG-PEG","slug":"ivig-peg","phase":"phase_3","mechanism":"IVIG-PEG is a polyethylene glycol-conjugated intravenous immunoglobulin that provides passive immune protection by delivering pooled human antibodies with extended half-life.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions"],"catalyst":""},{"name":"Immune Globulin (Human)","genericName":"Immune Globulin (Human)","slug":"immune-globulin-human","phase":"marketed","mechanism":"Immune Globulin (Human) provides passive immunization by supplying pooled human antibodies to enhance immune function and neutralize pathogens.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Chronic inflammatory demyelinating polyneuropathy (CIDP)","Immune thrombocytopenia (ITP)","Post-transfusion purpura"],"catalyst":""},{"name":"Prolastin-C","genericName":"Prolastin-C","slug":"prolastin-c","phase":"marketed","mechanism":"Prolastin-C is a purified human alpha-1 protease inhibitor (AAT) that replaces deficient or dysfunctional alpha-1 antitrypsin to protect lung tissue from enzymatic degradation.","indications":["Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Grifols Reports Fourth-Quarter and Full-Year 2023 Results","summary":"Grifols reported fourth-quarter and full-year 2023 results, with revenue of $2.4 billion and net income of $234 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-28","type":"deal","headline":"Grifols Acquires BioLife Plasma Services from Shire for $3.8 Billion","summary":"Grifols acquired BioLife Plasma Services from Shire for $3.8 billion, expanding its plasma collection network in the US.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"regulatory","headline":"FDA Approves Grifols' HyperRAB S/D for Rabies Prophylaxis","summary":"The FDA approved Grifols' HyperRAB S/D for rabies prophylaxis, expanding the company's portfolio of plasma-derived therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPazM4N1l3eTdLYVdzYy1FaUU1UzFubnlnM29oN2dVaEZEYUZMWTAtdWo2STBBTUVXUXVURW5KdWlBdkY0d2c0YnB5V2p3QXkwdER4U2hOYzAtSmVlY3hObzNkOHVNeHV5ai0zaE1ISEdSdEs0T1ZnWE42LUJBY0V2NlVTSUtLTjhVdXc?oc=5","date":"2025-10-09","type":"pipeline","source":"Yahoo Finance UK","summary":"Spanish court summons Gotham City founder in Grifols share price probe - Yahoo Finance UK","headline":"Spanish court summons Gotham City founder in Grifols share price probe","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-09","type":"pipeline","source":"simplywall.st","summary":"Grifols (BME:GRF) Valuation: Is Recent Momentum Signaling an Opportunity for Investors? - simplywall.st","headline":"Grifols (BME:GRF) Valuation: Is Recent Momentum Signaling an Opportunity for Investors?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOV0tRZnNxYTB4Zm9weGN2b3BrNmwzVnBvVGU5NlB0WnZENVB1eDVMdjFoMm9iRktFQVFBRElDNTlGUVlmTmlYS2xXNGQwM1VNZEN3NU84Q3NGN2UtSmNhMko1S05JZ0hyclRYM2tReXhVNk9hLTNPOVJsSHpyeE1yQVQtRmw0aDNDX1I2TjItZzJZdEJINmZza0NEUVZhTGR5c3pF?oc=5","date":"2023-02-16","type":"pipeline","source":"The Pharma Letter","summary":"Grifols announces 400-million-euro cost-saving initiative - The Pharma Letter","headline":"Grifols announces 400-million-euro cost-saving initiative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBYRUJ1bjFQSUF6b2JOV0c0UmxQaVRTRVF4bUZYUEZsNmY3YmdKWFM5UTdsNVNUMGdJS3dFRXo0eXZoZU5fUTlEN2lhM25EWmtTVWo4Ng?oc=5","date":"2017-06-08","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Solaria Energía y Medio Ambiente, S.A. (SLR.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Solaria Energía y Medio Ambiente, S.A. (SLR.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9XVHhhOEdWajhDamx1cHJFSzl0Y1VjamZ3d1N3bmRLal9ibDM3Y2M2eGprRzNNZ0Z3NDVaS1NXQWlXNEY0alFOMk1OQ3o1eUNqVTBlWA?oc=5","date":"2017-05-22","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Pharma Mar, S.A. (PHM.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5fLTk1UGVUOC0wSHlxeDktVU1OWENwUHR5eXEySm5lV3N4RWJYbVlqYXU5UHByNmVra05WN0V5WWN5a0p3T2tKQ2dEUnV1WUtjWHB1Xw?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharma Mar, S.A. (PHM.MC) stock price, news, quote and history - Yahoo Finance UK","headline":"Pharma Mar, S.A. (PHM.MC) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"RhoGAM","drugSlug":"rho(d)-immune-globulin-(human)","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"HyperRAB S/D","drugSlug":"rabies-immune-globulin-(human)","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000}],"drugCount":14,"phaseCounts":{"discontinued":1,"marketed":7,"phase_3":6},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Baxter International","BioLife Plasma Services","Octapharma"],"therapeuticFocus":["Plasma-Derived Therapies","Biologics"],"financials":{"source":"yahoo_finance","revenue":8789719633.2,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":8789719633.2},{"period":"2024-12-31","value":8425233651.6},{"period":"2023-12-31","value":7700934585.6},{"period":"2022-12-31","value":7084073603.7981}],"grossProfit":3339953273.7000003,"grossProfitHistory":[{"period":"2025-12-31","value":3339953273.7000003},{"period":"2024-12-31","value":3264018694.2000003},{"period":"2023-12-31","value":2900700936.9},{"period":"2022-12-31","value":2586109815.1530004}],"rdSpend":497663551.8000001,"rdSpendHistory":[{"period":"2025-12-31","value":497663551.8000001},{"period":"2024-12-31","value":448598131.20000005},{"period":"2023-12-31","value":461448598.50000006},{"period":"2022-12-31","value":421892523.702}],"sgaSpend":1241822430.9,"operatingIncome":1461448599.3000002,"operatingIncomeHistory":[{"period":"2025-12-31","value":1461448599.3000002},{"period":"2024-12-31","value":1349299066.5000002},{"period":"2023-12-31","value":838785047.4000001},{"period":"2022-12-31","value":793175234.2794001}],"netIncome":469626168.6,"netIncomeHistory":[{"period":"2025-12-31","value":469626168.6},{"period":"2024-12-31","value":183411215.10000002},{"period":"2023-12-31","value":49065420.6},{"period":"2022-12-31","value":216162383.35050002}],"eps":0.23,"epsHistory":[{"period":"2024-12-31","value":0.23},{"period":"2023-12-31","value":0.09},{"period":"2022-12-31","value":0.31},{"period":"2021-12-31","value":0.27}],"cash":935747664.3000001,"cashHistory":[{"period":"2025-12-31","value":935747664.3000001},{"period":"2024-12-31","value":1144859814},{"period":"2023-12-31","value":618664720.1211001},{"period":"2022-12-31","value":641596963.1301}],"totalAssets":23028037401.600002,"totalLiabilities":14146028048.7,"totalDebt":11175233653.800001,"equity":6157710285.3,"operatingCashflow":1223130842.1000001,"operatingCashflowHistory":[{"period":"2025-12-31","value":1223130842.1000001},{"period":"2024-12-31","value":1053738318.6000001},{"period":"2023-12-31","value":253504673.10000002},{"period":"2022-12-31","value":-1667056.0761000002}],"capex":-494158878.90000004,"capexHistory":[{"period":"2025-12-31","value":-494158878.90000004},{"period":"2024-12-31","value":-434579439.6},{"period":"2023-12-31","value":-362149533.00000006},{"period":"2022-12-31","value":-458962617.18960005}],"freeCashflow":728971963.2,"dividendsPaid":-149532710.4,"buybacks":0,"employees":25000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":181420560.8928,"ebit":255942757.21410003,"ebitda":405904205.9322,"period":"2025-12-31","revenue":2315023366.3380003,"epsBasic":null,"netIncome":114778037.47500001,"rdExpense":159740654.3334,"epsDiluted":null,"grossProfit":802384346.4363,"operatingIncome":321702103.0611},{"sga":330322430.17080003,"ebit":387779205.91770005,"ebitda":405658878.8292,"period":"2025-06-30","revenue":2209265188.6833,"epsBasic":0.17,"netIncome":136755841.23090002,"rdExpense":112375000.08990002,"epsDiluted":0.17,"grossProfit":868919393.2185,"operatingIncome":408342290.04630005},{"sga":184811916.03570002,"ebit":264497663.763,"ebitda":393155374.1463,"period":"2024-12-31","revenue":2308192758.8559003,"epsBasic":0.101363,"netIncome":80570093.5224,"rdExpense":134346962.72430003,"epsDiluted":0.101363,"grossProfit":895436916.6042001,"operatingIncome":446278037.74020004},{"sga":373160047.02750003,"ebit":370364486.27760005,"ebitda":496957944.32280004,"period":"2024-09-30","revenue":2094574768.0308,"epsBasic":0.076058,"netIncome":60386682.291300006,"rdExpense":102661215.0354,"epsDiluted":0.076058,"grossProfit":849012851.1465001,"operatingIncome":373191589.08360004}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.18,"previousClose":8.8,"fiftyTwoWeekHigh":13.7,"fiftyTwoWeekLow":8.43,"fiftyTwoWeekRange":"8.432 - 13.7","fiftyDayAverage":9.21,"twoHundredDayAverage":10.88,"beta":1.17,"enterpriseValue":20262923978.827164,"forwardPE":8,"priceToBook":1.18,"priceToSales":0.84,"enterpriseToRevenue":2.33,"enterpriseToEbitda":10.35,"pegRatio":0,"ebitda":1958213833.3422723,"ebitdaMargin":22.5,"freeCashflow":1036845084.9416257,"operatingCashflow":1192757010.3000002,"totalDebt":11295560980.999067,"debtToEquity":123.2,"currentRatio":2.47,"returnOnAssets":4.2,"returnOnEquity":6.1,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":14.65,"targetHighPrice":21.2,"targetLowPrice":9,"dividendRate":0.15,"payoutRatio":0.25,"fiveYearAvgDividendYield":1.48,"exDividendDate":1754870400,"insiderHeldPercent":31.9,"institutionHeldPercent":33.5,"sharesOutstanding":422351576,"floatShares":417315170,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.59,"epsForward":1.14,"revenuePerShare":10.93,"bookValue":7.75,"officers":[{"age":57,"name":"Mr. Jose Ignacio  Abia Buenache","title":"CEO & Director"},{"age":47,"name":"Mr. Rahul  Srinivasan","title":"Chief Financial Officer"},{"age":41,"name":"Mr. Lluis Pons Gomez","title":"Senior Vice President of Strategy & COO Office"},{"age":null,"name":"Daniel  Segarra","title":"Head of Investor Relations & Sustainability and Vice President"},{"age":71,"name":"Mr. David Ian Bell","title":"Chief Corporate Affairs & Legal Officer"},{"age":52,"name":"Mr. Enrique  de la Torre","title":"Chief Compliance Officer"},{"age":56,"name":"Ms. Montse  Ribas","title":"Chief Communications and Reputation Officer"},{"age":43,"name":"Mr. Camille  Alpi","title":"Chief Human Resources & Talent Officer"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.grifols.com","phone":"34 935 71 22 00"}}